Extension of Time to File SOU

SALIOGASE

Saliogen Therapeutics, Inc.

Request for Extension of Time to File a Statement of Use

PTO- 1581
Approved for use through 03/31/2024. OMB 0651-0054
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))


The table below presents the data as entered.

Input Field
Entered
SERIAL NUMBER 90517616
MARK SECTION
MARK SALIOGASE (see, http://uspto.report/TM/90517616/mark.png)
STANDARD CHARACTERS YES
USPTO-GENERATED IMAGE YES
LITERAL ELEMENT SALIOGASE
OWNER SECTION
NAME Saliogen Therapeutics, Inc.
MAILING ADDRESS 75 Hayden Avenue
CITY Lexington
STATE Massachusetts
ZIP/POSTAL CODE 02421
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
EMAIL XXXX
CORRESPONDENCE INFORMATION (current)
NAME Rachelle A. Dubow, Esq.
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE trademarks@morganlewis.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) rachelle.dubow@morganlewis.com; tricia.brown@morganlewis.com; jennifer.kagan@morganlewis.com
CORRESPONDENCE INFORMATION (proposed)
NAME Rachelle A. Dubow, Esq.
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE trademarks@morganlewis.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) rachelle.dubow@morganlewis.com; tricia.brown@morganlewis.com; jennifer.kagan@morganlewis.com
DOCKET/REFERENCE NUMBER 126933-0003
GOODS AND/OR SERVICES SECTION
INTERNATIONAL CLASS 001
CURRENT IDENTIFICATION Reagents, nucleic acids, and nucleotides for scientific and research use in the fields of clinical research, drug development, agriculture and genetics research; reagent kits comprised of reagents and chemical preparations for scientific research purposes; samples of nucleotide sequence variants and modified nucleotide sequences for use in the fields of scientific research, clinical research, and scientific diagnostics research
GOODS OR SERVICES KEEP ALL LISTED
INTERNATIONAL CLASS 005
CURRENT IDENTIFICATION Pharmaceutical preparations for genetically driven disorders, neurological, gastrointestinal, metabolic, immunological, dyslipidemias musculoskeletal, oncological disorders and diseases of the retina, liver, heart, lung, bone marrow, brain, muscle, immune system, and kidney; Reagents, nucleic acids, and nucleotides for medical and veterinary purposes
GOODS OR SERVICES KEEP ALL LISTED
EXTENSION SECTION
EXTENSION NUMBER 3
ONGOING EFFORT product or service research or development
ALLOWANCE MAIL DATE 12/14/2021
STATEMENT OF USE NO
PAYMENT SECTION
NUMBER OF CLASSES 2
SUBTOTAL AMOUNT [EXTENSION FEE] 250
TOTAL AMOUNT 250
SIGNATURE SECTION
SIGNATURE /Jeffrey Kopacz/
SIGNATORY'S NAME Jeffrey Kopacz
SIGNATORY'S POSITION Senior Vice President-Head of Intellectual Property & Contracts
DATE SIGNED 06/13/2023
SIGNATURE METHOD Sent to third party for signature
FILING INFORMATION
SUBMIT DATE Tue Jun 13 20:31:30 ET 2023
TEAS STAMP USPTO/ESU-XXX.XXX.XX.XXX-
20230613203130875560-9051
7616-850376ef17f7cd3e4c57
31bf38d8edac3227e867c94a1
78db7215d3a934be3b1c8a-DA
-31305701-202306132025027
53695



PTO- 1581
Approved for use through 03/31/2024. OMB 0651-0054
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number


SOU Extension Request
(15 U.S.C. Section 1051(d))


To the Commissioner for Trademarks:

MARK: SALIOGASE (see, http://uspto.report/TM/90517616/mark.png)
SERIAL NUMBER: 90517616

OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Saliogen Therapeutics, Inc., having an address of
      75 Hayden Avenue
      Lexington, Massachusetts 02421
      United States
      Email: XXXX

The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application.    The Notice of Allowance mailing date was 12/14/2021.

For International Class 001:
Current identification: Reagents, nucleic acids, and nucleotides for scientific and research use in the fields of clinical research, drug development, agriculture and genetics research; reagent kits comprised of reagents and chemical preparations for scientific research purposes; samples of nucleotide sequence variants and modified nucleotide sequences for use in the fields of scientific research, clinical research, and scientific diagnostics research

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


For International Class 005:
Current identification: Pharmaceutical preparations for genetically driven disorders, neurological, gastrointestinal, metabolic, immunological, dyslipidemias musculoskeletal, oncological disorders and diseases of the retina, liver, heart, lung, bone marrow, brain, muscle, immune system, and kidney; Reagents, nucleic acids, and nucleotides for medical and veterinary purposes

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


This is the third extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods/services covered by the extension request: product or service research or development

Correspondence Information (current)
      Rachelle A. Dubow, Esq.
      PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@morganlewis.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): rachelle.dubow@morganlewis.com; tricia.brown@morganlewis.com; jennifer.kagan@morganlewis.com
Correspondence Information (proposed)
      Rachelle A. Dubow, Esq.
      PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@morganlewis.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): rachelle.dubow@morganlewis.com; tricia.brown@morganlewis.com; jennifer.kagan@morganlewis.com

The docket/reference number is 126933-0003.

Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).




A fee payment in the amount of $250 will be submitted with the form, representing payment for 2 classes.


Declaration

STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section 1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.

DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made on information and belief are believed to be true.


Signature: /Jeffrey Kopacz/      Date Signed: 06/13/2023
Signatory's Name: Jeffrey Kopacz
Signatory's Position: Senior Vice President-Head of Intellectual Property & Contracts
Signature method: Sent to third party for signature

PAYMENT: 90517616
PAYMENT DATE: 06/13/2023

Serial Number: 90517616
Internet Transmission Date: Tue Jun 13 20:31:30 ET 2023
TEAS Stamp: USPTO/ESU-XXX.XXX.XX.XXX-202306132031308
75560-90517616-850376ef17f7cd3e4c5731bf3
8d8edac3227e867c94a178db7215d3a934be3b1c
8a-DA-31305701-20230613202502753695




uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed